Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT04722341

Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators

Led by Cedars-Sinai Medical Center · Updated on 2025-12-16

175

Participants Needed

2

Research Sites

260 weeks

Total Duration

On this page

Sponsors

C

Cedars-Sinai Medical Center

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to test whether the timing of meals can improve treatment adverse events, influence tumor biology and alter a person's mood and behaviors.

CONDITIONS

Official Title

Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Any sex or gender and any ethnic or racial background
  • Age 18 years or older
  • Histologically confirmed rectal cancer stage II, III, or IV (if curative intent) or HER2-positive or triple negative breast cancer stage I, II, or III (only if definitive intent) per AJCC criteria
  • Body mass index (BMI) of 18.5 kg/m2 or greater
  • Receiving neoadjuvant therapy with curative intent (breast cancer) or total neoadjuvant therapy with a 5-fluorouracil-based regimen and curative intent (rectal cancer)
  • Completed 4 weeks or less of neoadjuvant treatment before study enrollment
  • Willing and able to follow assessments, visit schedules, and study requirements
Not Eligible

You will not qualify if you...

  • Received cytotoxic chemotherapy within 12 months prior to rectal or breast cancer diagnosis
  • Allergic reaction to any treatment agents
  • Previous pelvic radiotherapy
  • Active second cancer other than non-melanoma skin cancer or cervical carcinoma in situ
  • History of gastrointestinal perforation within 12 months before enrollment
  • Severe or rapidly worsening predisposing colonic or small bowel disorders unrelated to current cancer symptoms
  • Receiving parenteral nutrition, enteral feeding, or similar supplements during the study
  • History of uncontrolled congestive heart failure (NYHA Class III or greater)
  • Pre-existing grade 3 or higher neuropathy
  • Participation in another investigational drug or device study within 4 weeks before first treatment dose
  • Pregnant or breastfeeding
  • Working overnight shifts more than one day per week on average
  • Strictly following a less than 10-hour eating window on most days
  • Psychiatric or substance abuse disorders that interfere with study adherence
  • Medical conditions or lab abnormalities that could affect safety or data validity as judged by investigators

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

The University of Alabama at Birmingham

Birmingham, Alabama, United States, 35294

Actively Recruiting

2

Cedars-Sinai Medical Center

West Hollywood, California, United States, 90048

Actively Recruiting

Loading map...

Research Team

N

Nathalie Nguyen, MPH

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here